AnteCancerW

225.00
Product price
Additional options total:
Order total:

AnteCancerW is a set of genetic risk tests for women to assess the risk of developing breast, colorectal cancer and melanoma. This package includes AnteBC, AnteCRC and AnteMEL genetic risk tests.

What does AnteCancerW test include?

  • Analyzes of:
    • 2803 genetic variants associated with breast cancer;
    • 91 genetic variants associated with colorectal cancer;
    • 28 genetic variants associated with melanoma.
  • Personal polygenic risk scores for breast, colorectal cancer and melanoma.
  • The individual risk of:
    • breast cancer compared to the rest of the female population;
    • colorectal cancer compared to the rest of the population;
    • melanoma compared to the rest of the population.
  • Likelihood to get:
    • breast cancer in 10 years and risk assessment compared to a woman with average genetic risk;
    • colorectal cancer in 10 years and risk assessment compared to a person with average genetic risk;
    • melanoma in 10 years and risk assessment compared to a person with average genetic risk.
  • Interpretation of the test results with clinical recommendations.
  • Genetic counseling.

Who can benefit from AnteCancerW?

Recommended for women aged 35-70 with European ancestry.

What is needed for AnteCancerW testing?

Testing requires the your DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).

How long does it take to get AnteCancerW test results?

Test results are available within 6 weeks from the sample being received by Antegenes.

What is the science behind the AnteCancerW test?

  • The research describing the development of AnteBC test is available at medRxiv
  • The research describing the development of AnteCRC test is available at medRxiv
  • The research describing the development of AnteMEL test is available at medRxiv

AnteCancerW Test Limitations

  • AnteCancerW test is not used to diagnose breast, colorectal cancer and melanoma.
  • AnteCancerW test is not validated for use by individuals of non-European descent.
  • An elevated risk estimated by the AnteCancerW test does not mean that you will develop breast, colorectal cancer or melanoma during your lifetime. Also, a moderate or lower risk does not mean that the probability of developing the diseases is zero.
  • AnteCancerW test does not assess the risk of your family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
  • AnteCancerW does not analyze rare pathogenic mutations in breast, colorectal and melanoma genes that significantly increase the risk of developing the cancers.
  • The AnteCancerW test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
  • Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
  • The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of breast, colorectal cancer and melanoma.

CE

AnteCancerW